Attachment: Product Information: Nivolumab
Treatment was continued as long as clinical benefit was observed or until treatment was no longer tolerated. Tumour assessments were conducted 12 weeks after randomisation then every 6 weeks for the first year, and every 12 weeks thereafter. The co-primary outcome measures were PFS and OS. ORR and the duration of response were also assessed. ................
................
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- april 2017 north west postgraduate medicine and dentistry
- university of toronto
- deep neck infections ent lectures
- idsa emerging infections network
- attachment product information nivolumab
- МІНІСТЕРСТВО ОХОРОНИ ЗДОРОВ Я УКРАЇНИ
- ministry of public health of ukraine
- evaluation and management of the medically complex patient
- m29 1 part 5 a
- purpose home veterans affairs
Related searches
- attachment style quiz
- attachment style quiz printable
- reactive attachment disorder
- reactive attachment disorder in adults
- reactive attachment disorder checklist
- interventions for reactive attachment disorder
- attachment disorder in children interventions
- reactive attachment disorder therapy techniques
- strategies for reactive attachment disorder
- reactive attachment disorder define
- attachment disorder in children symptoms
- symptoms of reactive attachment disorder